Combination therapy using JAK2 and HSP90 inhibitors increased efficacy in myelofibrosis in vivo - Protein kinase inhibitors - Document - PDFSEARCH.IO

First Page	Meta Content
	Combination therapy using JAK2 and HSP90 inhibitors increased efficacy in myelofibrosis in vivo Add to Reading List Document Date: 2015-03-04 03:17:09 Open Document File Size: 17,62 KB Share Result on Facebook Facility Memorial Sloan-Kettering Cancer Center / / MedicalCondition chronic ruxolitinib therapy / scar / cancer / chronic malignant blood disorder / infection / blood cancers / inflammation / different cancer / anemia / myelofibrosis / / Organization American Society of Hematology APA / Leukemia Service / Memorial Sloan-Kettering Cancer Center in New York / / Person Priya Koppikar / Ross Levine / / Position second author / lead author and Associate Attending Physician / / URL www.tcpdf.org / http / SocialTag Janus kinase inhibitor Hsp90 inhibitors Janus kinase 2 Hsp90 Myelofibrosis Heat shock protein Essential thrombocytosis Medicine Biology Ruxolitinib

Combination therapy using JAK2 and HSP90 inhibitors increased efficacy in myelofibrosis in vivoAdd to Reading List